Advances in Pulmonology and Lung Surgery

Among the top pulmonology & lung surgery hospitals in New York and the country.

Our program is led by renowned physicians and a comprehensive multidisciplinary team. With expert leadership, a strong research component, and unsurpassed patient survival rates, our lung transplantation program has been top-ranked in the Nation for the past 10 years.

image of bacteria Streptococcus pneumoniae, or pneumococcus

An Expert Makes the Case for Pneumococcal Vaccinations

Weill Cornell Medicine pulmonologist leads a comprehensive review of effectiveness and efficacy of the 23-valent polysaccharide vaccine.

image of lung cells damaged by COVID-19 undergoing analysis

Novel Technique Provides Insights into Lung Pathology in COVID-19

Investigators at Weill Cornell Medicine and NewYork-Presbyterian used advanced technology and analytics to map, at single-cell resolution, the cellular landscape of diseased lung tissue in severe COVID-19 and other infectious lung diseases.

vector image of coronavirus

COVID-19: One Year Later

Pulmonologists and critical care medicine specialists at NewYork-Presbyterian Hospital, Columbia University, and Weill Cornell Medicine continue to share their observations and present their research findings on severe acute respiratory syndrome coronavirus 2.

image of Dr. Selim M. Arcasoy

Lung Transplantation: Decades of Experience and Expertise

Since the inception of the new program nearly two decades ago, the Lung Transplantation Program at NewYork-Presbyterian/Columbia has performed more than 900 lung transplants with survival rates that far surpass national averages.

image of Dr. Sanja J. Jelic

Sleep and Cardiovascular Risk: A Causal Relationship?

Sleep is increasingly recognized as an important contributor to health, yet many Americans regularly do not get enough sleep. To learn if inadequate sleep increases their risks of heart disease, NYP Columbia study the relationship between sleep habits and cardiovascular risk factors.

image of Dr. Robert J. Kaner

IPF: Looking to the Microbiome for New Treatments

Despite years of investigations, the origin of idiopathic pulmonary fibrosis has remained elusive. Researchers at NewYork-Presbyterian/Weill Cornell are looking into new therapies to slow the progression.

Newsletters for Medical Professionals

2022 Issue 1

2021 Issue 2

2021 Issue 1

2018 Issue 2

2018 Issue 1

2017 Issue 1

Spring/Summer 2016